Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Sponsor: Massachusetts General Hospital
Listed as NCT04259255, this observational or N/A phase trial focuses on ALS and Amyotrophic Lateral Sclerosis and remains ongoing. Sponsored by Massachusetts General Hospital, it has been updated 16 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Jan 2026 — Present [monthly]
Unknown
-
Oct 2025 — Jan 2026 [monthly]
Unknown
Status: Active Not Recruiting → Unknown
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
▶ Show 11 earlier versions
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Sep 2023 [monthly]
Recruiting
-
Sep 2022 — Feb 2023 [monthly]
Recruiting
-
Jan 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2021 — Jan 2022 [monthly]
Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Recruiting
-
Apr 2020 — Aug 2020 [monthly]
Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Recruiting
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- Tanabe Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .